Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-06-28 Purchase | 2023-06-30 09:25 am | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 500,000 | $0.02175 | $10,875 | 115,272,130 (Indirect Direct) | View |
| 2023-06-16 Purchase | 2023-06-20 12:00 pm | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 100,000 | $0.026 | $2,600 | 115,197,130 (Indirect Direct) | View |
| 2023-06-14 Purchase | 2023-06-16 12:00 pm | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 400,000 | $0.0326 | $13,040 | 115,097,130 (Indirect Direct) | View |
| 2023-05-26 Purchase | 2023-05-31 09:39 am | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 126,888 | $0.0341 | $4,327 | 114,697,130 (Indirect Direct) | View |
| 2023-05-02 Purchase | 2023-05-02 5:00 pm | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 100,000 | $0.045 | $4,500 | 114,570,242 (Indirect Direct) | View |
| 2022-12-06 Purchase | 2022-12-07 08:00 am | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 120,000 | $0.05 | $6,000 | 114,210,934 (Indirect Direct) | View |
| 2022-11-22 Purchase | 2022-11-25 09:00 am | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 70,000 | $0.08 | $5,600 | 114,090,934 (Indirect Direct) | View |
| 2022-09-26 Purchase | 2022-09-28 09:15 am | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 20,000 | $0.068 | $1,360 | 114,020,934 (Indirect Direct) | View |
| 2022-08-25 Purchase | 2022-08-29 09:15 am | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 80,000 | $0.082 | $6,560 | 114,000,934 (Indirect Direct) | View |
| 2020-11-20 Purchase | 2020-11-24 5:30 pm | MATEON THERAPEUTICS INC | MATN | Shah Amit B. CHIEF FINANCIAL OFFICER | 60,000 | $0.19264 | $11,558 | 60,000 (Direct) | View |
| 2020-11-19 Purchase | 2020-11-23 3:01 pm | MATEON THERAPEUTICS INC | MATN | Park Chulho CHIEF TECHNOLOGY OFFICER | 22,173 | $0.1848 | $4,098 | 2,833,992 (Direct) | View |
| 2020-11-19 Purchase | 2020-11-23 3:01 pm | MATEON THERAPEUTICS INC | MATN | Trieu Vuong CHIEF EXECUTIVE OFFICER | 50,500 | $0.19 | $9,595 | 19,944,035 (Indirect Direct) | View |
| 2020-03-26 Purchase | 2020-03-27 5:49 pm | MATEON THERAPEUTICS INC | MATN | Trieu Vuong CHIEF EXECUTIVE OFFICER | 3,000 | $0.12 | $360 | 19,893,535 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2021-09-03 Option Award | 2021-09-08 5:00 pm | N/A 2031-09-03 | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong Chief Executive Officer | 225,000 | $0 | 225,000 (Direct) | View |
| 2021-09-03 Option Award | 2021-09-08 5:00 pm | N/A 2031-09-03 | Oncotelic Therapeutics Inc. | OTLC | MAIDA ANTHONY E III Chief Clin. Ops. Officer | 600,000 | $0 | 600,000 (Direct) | View |
| 2021-09-03 Option Award | 2021-09-08 5:00 pm | N/A 2031-09-03 | Oncotelic Therapeutics Inc. | OTLC | KING STEVEN W Director | 500,000 | $0 | 500,000 (Direct) | View |
| 2021-09-03 Option Award | 2021-09-08 5:00 pm | N/A 2031-09-03 | Oncotelic Therapeutics Inc. | OTLC | Saund Saran Chief Business Officer | 675,000 | $0 | 675,000 (Direct) | View |
| 2021-03-31 Conversion | 2021-07-16 5:39 pm | N/A N/A | Oncotelic Therapeutics Inc. | OTLC | MAIDA ANTHONY E III CHIEF CLINICAL OFFICER | 939,584 | $0 | 1,537,314 (Direct) | View |
| 2021-07-08 Option Award | 2021-07-16 5:39 pm | 2021-07-08 2031-07-08 | Oncotelic Therapeutics Inc. | OTLC | MAIDA ANTHONY E III CHIEF CLINICAL OFFICER | 400,000 | $0 | 1,537,314 (Direct) | View |
| 2021-03-31 Conversion | 2021-07-16 5:38 pm | N/A N/A | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 94,070,882 | $0 | 97,913,805 (Direct) | View |
| 2021-07-08 Option Award | 2021-07-16 5:38 pm | 2021-07-08 2031-07-08 | Oncotelic Therapeutics Inc. | OTLC | Trieu Vuong CHAIRMAN AND CEO 10% Owner | 773,255 | $0 | 97,913,805 (Direct) | View |
| 2021-03-31 Conversion | 2021-07-16 5:37 pm | N/A N/A | Oncotelic Therapeutics Inc. | OTLC | KING STEVEN W Director | 3,295,012 | $0 | 3,688,059 (Indirect) | View |
| 2021-07-08 Option Award | 2021-07-16 5:37 pm | 2021-07-08 2031-07-08 | Oncotelic Therapeutics Inc. | OTLC | KING STEVEN W Director | 357,412 | $0 | 3,688,059 (Direct) | View |
| 2021-07-08 Option Award | 2021-07-16 5:37 pm | 2021-07-08 2031-07-08 | Oncotelic Therapeutics Inc. | OTLC | Shah Amit B. CHIEF FINANCIAL OFFICER | 997,093 | $0 | 1,057,093 (Direct) | View |
| 2021-07-08 Option Award | 2021-07-16 5:36 pm | 2021-07-08 2031-07-08 | Oncotelic Therapeutics Inc. | OTLC | Diamond David Director | 451,467 | $0 | 451,467 (Direct) | View |
| 2021-03-31 Conversion | 2021-07-16 5:35 pm | N/A N/A | Oncotelic Therapeutics Inc. | OTLC | Saund Saran CHIEF BUSINESS OFFICER | 16,371,316 | $0 | 16,673,759 (Direct) | View |
| 2021-07-08 Option Award | 2021-07-16 5:35 pm | 2021-07-08 2031-07-08 | Oncotelic Therapeutics Inc. | OTLC | Saund Saran CHIEF BUSINESS OFFICER | 318,798 | $0 | 16,673,759 (Direct) | View |
Ownership | 2020-05-21 8:29 pm | N/A N/A | MATEON THERAPEUTICS INC | MATN | MAIDA ANTHONY E III Director | 0 | $0 | 1,137,314 (Direct) | View |
Ownership | 2020-05-21 8:27 pm | N/A N/A | MATEON THERAPEUTICS INC | MATN | KING STEVEN W Director | 0 | $0 | 4,618,424 (Direct) | View |